Associate Professor of Urology
Johns Hopkins Medical Institutions
Dr. Jun Luo is a cell and molecular biologist by training with a broad background in prostate tumor biology, genomics, and genetics. He received his Ph.D. in Anatomy and Cell Biology in 1999. His Ph.D. thesis work focused on the role of cell-cell adhesion mediated by E-cadherin using the Dunning prostate cancer invasion model (Mentored by Dr. Mary J.C. Hendrix at the University of Iowa). He joined the Brady Urological Institute first as a postdoctoral fellow with Dr. William B. Isaacs. While a fellow (1999-2002) he was also a Guest Researcher at the National Human Genome Research Institute (NHGRI). Dr. Luo conducted one of the first high-density expression microarray studies on prostate cancer during this period. This study led to the discovery of a highly sensitive and specific prostate cancer tissue marker named AMACR, which has since been widely adopted as an ancillary tool in Surgical Pathology.
Dr. Luo joined the faculty at Brady in 2002. Research efforts in his laboratory continue to focus on the problem of prostate cancer through discovery, development, and clinical implementation of molecular tools for diagnosis, prognosis, and therapeutic prediction. The guiding concept for his research is that the clinical course of cancer progression is determined, and also accompanied, by dynamic interactions among genetic, epigenetic, and environmental factors that are ultimately manifested in the transcriptional phenotype. Dr. Luo employs cutting-edge technologies to investigate the prostate tumor transcriptional phenotype. Through a network of collaborators, Dr. Luo uses new knowledge gained from these studies as the basis for developing precision tools and molecular markers pertaining to prostate cancer management in a variety of clinical settings.
His main research interests are:
- Androgen receptor splice variants in contemporary clinical care of men with castration-resistant prostate cancer.
- Genomic profiles underlying natural history of prostate cancer progression and disease disparity by geographical ancestry.
- RNA sequencing technologies.
- Circulating tumor cells.